<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intestinal marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of the MALT type (I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>) is a relatively uncommon form of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-seven patients with histologically-confirmed I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> were analyzed </plain></SENT>
<SENT sid="2" pm="."><plain>The patients initially presented with <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> (62.9%), and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (22.2%) </plain></SENT>
<SENT sid="3" pm="."><plain>The most common involved site was the ileo-caecal area (40.7%) </plain></SENT>
<SENT sid="4" pm="."><plain>Musshoff's stage I(E), II(E)1, II(E)2, III(E) and IV were present in 44%, 15%, 11%, 7.4% and 22% respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Sixty-three percent were in the low-risk group according to the Follicular <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> International Prognostic Index </plain></SENT>
<SENT sid="6" pm="."><plain>Complete response and partial response were achieved in 82% and 4% patients </plain></SENT>
<SENT sid="7" pm="."><plain>The estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were 86% and 54% </plain></SENT>
<SENT sid="8" pm="."><plain>Stage &gt; or = II(E)2 was determined to be a poor prognostic factor for PFS and OS </plain></SENT>
<SENT sid="9" pm="."><plain>I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> commonly manifests in an early-stage, low-risk state and tends to respond well to local and systemic treatment with favorable prognosis </plain></SENT>
<SENT sid="10" pm="."><plain>I-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e> tends to be an indolent disease - characterized by prolonged survival with frequent relapses, similarly to other site <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZLs</z:e> </plain></SENT>
</text></document>